Selected research
Industry Research
Aptamer CDMO Industry Research Report 2026
Market perspective
The global Aptamer CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Aptamer CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Aptamer CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Aptamer CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Aptamer CDMO include AMSBIO, Aptagen, Aptamer Group, PORTON, Base Pair, Base Pair Biotechnologies, Cambio, CD Bioparticles and Creative Biolabs, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Aptamer CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Aptamer CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Aptamer CDMO Market by Company
AMSBIO
Aptagen
Aptamer Group
PORTON
Base Pair
Base Pair Biotechnologies
Cambio
CD Bioparticles
Creative Biolabs
Eurogentec
Novaptech
Aptamer CDMO Segment by Type
RNA Aptamer CDMO
DNA Aptamer CDMO
Others
Aptamer CDMO Segment by Application
Scientific Research
Medical Treatment
Others
Aptamer CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aptamer CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Aptamer CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aptamer CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Aptamer CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Aptamer CDMO
- DNA Aptamer CDMO
- Others
Applications
- Scientific Research
- Medical Treatment
- Others
Companies covered
- AMSBIO
- Aptagen
- Aptamer Group
- PORTON
- Base Pair
- Base Pair Biotechnologies
- Cambio
- CD Bioparticles
- Creative Biolabs
- Eurogentec
- Novaptech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Aptamer CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 RNA Aptamer CDMO
- 2.2.3 DNA Aptamer CDMO
- 2.2.4 Others
- 2.3 Aptamer CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Scientific Research
- 2.3.3 Medical Treatment
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Aptamer CDMO Breakdown Data by Type
- 3.1 Global Aptamer CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Aptamer CDMO Forecasted Market Size by Type (2027-2032)
4 Aptamer CDMO Breakdown Data by Application
- 4.1 Global Aptamer CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Aptamer CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Aptamer CDMO Market Perspective (2021-2032)
- 5.2 Global Aptamer CDMO Growth Trends by Region
- 5.2.1 Global Aptamer CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Aptamer CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Aptamer CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Aptamer CDMO Market Dynamics
- 5.3.1 Aptamer CDMO Industry Trends
- 5.3.2 Aptamer CDMO Market Drivers
- 5.3.3 Aptamer CDMO Market Challenges
- 5.3.4 Aptamer CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Aptamer CDMO Players by Revenue
- 6.1.1 Global Top Aptamer CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Aptamer CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Aptamer CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Aptamer CDMO Head Office and Area Served
- 6.4 Global Aptamer CDMO Players, Product Type & Application
- 6.5 Global Aptamer CDMO Manufacturers Established Date
- 6.6 Global Aptamer CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Aptamer CDMO Market Size (2021-2032)
- 7.2 North America Aptamer CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Aptamer CDMO Market Size by Country (2021-2026)
- 7.4 North America Aptamer CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Aptamer CDMO Market Size (2021-2032)
- 8.2 Europe Aptamer CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Aptamer CDMO Market Size by Country (2021-2026)
- 8.4 Europe Aptamer CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Aptamer CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Aptamer CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Aptamer CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Aptamer CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Aptamer CDMO Market Size (2021-2032)
- 10.2 South America Aptamer CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Aptamer CDMO Market Size by Country (2021-2026)
- 10.4 South America Aptamer CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Aptamer CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Aptamer CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Aptamer CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Aptamer CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AMSBIO
- 12.1.1 AMSBIO Company Information
- 12.1.2 AMSBIO Business Overview
- 12.1.3 AMSBIO Revenue in Aptamer CDMO Business (2021-2026)
- 12.1.4 AMSBIO Aptamer CDMO Product Portfolio
- 12.1.5 AMSBIO Recent Developments
- 12.2 Aptagen
- 12.2.1 Aptagen Company Information
- 12.2.2 Aptagen Business Overview
- 12.2.3 Aptagen Revenue in Aptamer CDMO Business (2021-2026)
- 12.2.4 Aptagen Aptamer CDMO Product Portfolio
- 12.2.5 Aptagen Recent Developments
- 12.3 Aptamer Group
- 12.3.1 Aptamer Group Company Information
- 12.3.2 Aptamer Group Business Overview
- 12.3.3 Aptamer Group Revenue in Aptamer CDMO Business (2021-2026)
- 12.3.4 Aptamer Group Aptamer CDMO Product Portfolio
- 12.3.5 Aptamer Group Recent Developments
- 12.4 PORTON
- 12.4.1 PORTON Company Information
- 12.4.2 PORTON Business Overview
- 12.4.3 PORTON Revenue in Aptamer CDMO Business (2021-2026)
- 12.4.4 PORTON Aptamer CDMO Product Portfolio
- 12.4.5 PORTON Recent Developments
- 12.5 Base Pair
- 12.5.1 Base Pair Company Information
- 12.5.2 Base Pair Business Overview
- 12.5.3 Base Pair Revenue in Aptamer CDMO Business (2021-2026)
- 12.5.4 Base Pair Aptamer CDMO Product Portfolio
- 12.5.5 Base Pair Recent Developments
- 12.6 Base Pair Biotechnologies
- 12.6.1 Base Pair Biotechnologies Company Information
- 12.6.2 Base Pair Biotechnologies Business Overview
- 12.6.3 Base Pair Biotechnologies Revenue in Aptamer CDMO Business (2021-2026)
- 12.6.4 Base Pair Biotechnologies Aptamer CDMO Product Portfolio
- 12.6.5 Base Pair Biotechnologies Recent Developments
- 12.7 Cambio
- 12.7.1 Cambio Company Information
- 12.7.2 Cambio Business Overview
- 12.7.3 Cambio Revenue in Aptamer CDMO Business (2021-2026)
- 12.7.4 Cambio Aptamer CDMO Product Portfolio
- 12.7.5 Cambio Recent Developments
- 12.8 CD Bioparticles
- 12.8.1 CD Bioparticles Company Information
- 12.8.2 CD Bioparticles Business Overview
- 12.8.3 CD Bioparticles Revenue in Aptamer CDMO Business (2021-2026)
- 12.8.4 CD Bioparticles Aptamer CDMO Product Portfolio
- 12.8.5 CD Bioparticles Recent Developments
- 12.9 Creative Biolabs
- 12.9.1 Creative Biolabs Company Information
- 12.9.2 Creative Biolabs Business Overview
- 12.9.3 Creative Biolabs Revenue in Aptamer CDMO Business (2021-2026)
- 12.9.4 Creative Biolabs Aptamer CDMO Product Portfolio
- 12.9.5 Creative Biolabs Recent Developments
- 12.10 Eurogentec
- 12.10.1 Eurogentec Company Information
- 12.10.2 Eurogentec Business Overview
- 12.10.3 Eurogentec Revenue in Aptamer CDMO Business (2021-2026)
- 12.10.4 Eurogentec Aptamer CDMO Product Portfolio
- 12.10.5 Eurogentec Recent Developments
- 12.11 Novaptech
- 12.11.1 Novaptech Company Information
- 12.11.2 Novaptech Business Overview
- 12.11.3 Novaptech Revenue in Aptamer CDMO Business (2021-2026)
- 12.11.4 Novaptech Aptamer CDMO Product Portfolio
- 12.11.5 Novaptech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst